Eli Lilly, Medicine, Drug, Pharmaceutical drug, Lilly Endowment, Company
Can a small band of biopharma players succeed where Eli Lilly failed? They’re taking a shot
Eli Lilly didn’t try to spin anything about the mid-stage data they got on their CHK1/CHK2 drug prexasertib for ovarian cancer patients. The drug failed to move the dial in a significant fashion and they unceremoniously swept it right out of the pipeline a little more than 2 years ago.
Can a small band of biopharma players succeed where Eli Lilly failed? They’re taking a shot
Eli Lilly didn’t try to spin anything about the mid-stage data they got on their CHK1/CHK2 drug prexasertib for ovarian cancer patients. The drug failed to move the dial in a significant ...
We are sorry, we could not find the related article
If you are curious about Biotech Essentials and Career and Jobs
Please click on:
Or signup to our newsletters
Lilly kicks off 2020’s predicted biopharma M&A boom with $1.1B Dermira deal
Eli Lilly is picking up Dermira for $1.1 billion, or $18.75 a share, more than double the value at which it was trading a month ago. Analysts expected the company to pursue oncology assets, ...
Eli Lilly lines up a blockbuster deal for Covid-19 antibody, right after it failed a NIAID trial
Two days after Eli Lilly conceded that its antibody bamlanivimab was a flop in hospitalized Covid-19 patients, the US government is preparing to make it a blockbuster. The pharma giant ...
“If Grandma Is on the Table, No One Will Blink at the Price” A Former Drug Company Manager Talks About Price-Setting
Frances Leath no longer works in management for pharmaceutical industry giant Eli Lilly and Company, but she keeps tabs on the company where she spent the first 15 years of her career. She ...
Lilly cancer drug fails key trial, will no longer be prescribed
Eli Lilly and Co said on Friday that its cancer treatment Lartruvo, which had wo...
The man who founded a biotech that got sold to Eli Lilly for $8 billion reveals why he's staying on at the pharma giant
Now the head of the Loxo Oncology organization at Lilly, Josh Bilenker shares his advice for other founders who want to stay on after an acquisition.
Shifts in pharma’s 2020 digital health landscape
Former health innovation executive Naomi Fried highlights trends to watch among pharmas interested in digital health technologies.
Eli Lilly to Close UK Research Center, Affecting 270 Staffers
The facility is expected to close by the end of 2020, affecting 270 staffers, with 80 possible redundancies.
Lilly’s $8 billion Loxo deal turned into an acqui-hire
First Eli Lilly paid $8 billion for Loxo Oncology. Pharma companies buy biotechs for the drugs, not the people, and founders usually cash out and move on to the next thing. But after the ...
Pharma Stocks Soothe Stock-Market Malady
Pharmaceutical stocks have been a safe harbor in a choppy stock market, and for good reason.
Apple teams up with Eli Lilly to study how iPhone and Apple Watch can help detect dementia
Apple has teamed up with Eli Lilly to study whether the Apple Watch and iPhone can be effectively used to spot early signs of dementia.
Eli Lilly to shut down UK-based neuroscience R&D centre, cut jobs
FirstWord Pharma - Gain Access to the Information You Need Track the Companies, Products, and Regulatory Areas of Most Interest to You